مباشر

FierceBiotechASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer BioPharma DiveFulcrum exploring a potential sale after FDA sidelined its sickle cell drug Endpoints NewsWhat’s next for VEGF? #ASCO26 offered clues, but answers will have to wait FierceBiotechTravere scales Everest with $1.1B deal for BTK inhibitor aimed at rare kidney diseases Endpoints NewsMale contraception startup closes $92.5M Series B; Novartis bets on actinium Endpoints NewsTravere pays Everest $112M upfront to grow rare kidney disease pipeline Endpoints NewsLegend Biotech shares first in vivo CAR-T data, its next act after Carvykti FierceBiotechFulcrum scraps SCD program, considers options after FDA takes hard line on safety risks FierceBiotechASCO: Cardiff posts updated colorectal cancer data ahead of pivotal push PharmaVoiceAs amyloid falls out of favor, here’s where Alzheimer’s R&D is headed next BioWorldJanssen Pharmaceutica reports new TMEM175 activators BioWorldBlossomhill Therapeutics discovers new EGFR mutant inhibitors

Labiotech ٢ يونيو ٢٠٢٦

The biggest biotech funding rounds in May 2026

Isomorphic Labs, Apogee Therapeutics, and Avalo Therapeutics bagged the biggest biotech funding rounds overall in May 2026. The post The biggest biotech funding...

Isomorphic Labs, Apogee Therapeutics, and Avalo Therapeutics bagged the biggest biotech funding rounds overall in May 2026. The post The biggest biotech funding rounds in May 2026 appeared first on Labiotech.eu . © Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.